Showing results (111-120 of 131) with videos related to
Sort By:
Pageof 14
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 16, 2025
Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMSDouglas L Arnold, Shannon Kolind, Haz-Edine Assemlal, et al.CNS Drugs|January 19, 2020
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 StudyRobert T Naismith, Annette Wundes, Tjalf Ziemssen, et al.The New England Journal of Medicine|September 13, 2018
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple SclerosisTanuja Chitnis, Douglas L Arnold, Brenda Banwell, et al.Annals of Neurology|November 12, 2005
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"Chris H Polman, Stephen C Reingold, Gilles Edan, et al.Annals of Neurology|March 10, 2011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaChris H Polman, Stephen C Reingold, Brenda Banwell, et al.Journal of Neurology, Neurosurgery, and Psychiatry|March 6, 2020
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS studyDouglas L Arnold, Brenda Banwell, Amit Bar-Or, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 8, 2020
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS studyTanuja Chitnis, Brenda Banwell, Lauren Krupp, et al.Lancet (London, England)|February 1, 2016
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin, David H Miller, Mark S Freedman, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2019
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 studyRobert T Naismith, Jerry S Wolinsky, Annette Wundes, et al.The Lancet. Neurology|September 22, 2024
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trialsXavier Montalban, Patrick Vermersch, Douglas L Arnold, et al.Pageof 14